Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8568-8581
DOI: 10.1007/s00259-026-08177-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.09.2026. Verfasst von Ye Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Triple Negative Breast Neoplasms, Nectins. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Key Program of National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Nuclear Technology R&D Program.
Abstract (Originalsprache)
Purpose
Nectin-4 has emerged as an attractive diagnostic and therapeutic target in a wide range of malignancies. Herein, we aimed to evaluate the clinical utility of a novel Nectin-4-targeted radiotracer, [^68Ga]Ga-FZ-NR-1, for non-invasive whole-body mapping, head-to-head diagnostic comparison with [^18F]FDG, and survival prediction in recurrent or metastatic triple-negative breast cancer (TNBC).
Methods
40 patients with recurrent or metastatic TNBC who underwent [^68Ga]Ga-FZ-NR-1 and [^18F]FDG PET/CT within 1 week were enrolled in this clinical translational study. Diagnostic performance was compared using the McNemar test. The survival analyses were performed using the Kaplan-Meier method. Results [^68Ga]Ga-FZ-NR-1 PET/CT revealed high intra-patient spatial heterogeneity of Nectin-4 expression, yielding a median inter-lesion fold difference of 3.10 and a median coefficient of variation of 31.70%. Although a higher SUV_max was observed with [^18F]FDG, [^68Ga]Ga-FZ-NR-1 achieved a significantly higher tumor-to-background ratio across various metastatic sites. Therefore, [^68Ga]Ga-FZ-NR-1 PET/CT detected more lesions than [^18F]FDG PET/CT and showed better sensitivity and specificity (98.13% vs.93.46% and 68.63% vs. 27.45%, respectively). Furthermore, high baseline mean MTV_40 ([^68Ga]Ga-FZ-NR-1) and HI ([^68Ga]Ga-FZ-NR-1) predicted significantly shorter progression-free survival ( P = 0.009) and overall survival ( P = 0.008), respectively. Conclusion [^68Ga]Ga-FZ-NR-1 PET/CT demonstrates improved diagnostic performance and independent prognostic value compared to [^18F]FDG in recurrent or metastatic TNBC. These hypothesis-generating findings suggest that it holds potential as a non-invasive imaging biomarker to aid future risk stratification and patient selection for Nectin-4-targeted therapies. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Center for Biomedical Imaging, Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. xxp0012@ustc.edu.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. xxp0012@ustc.edu.
Förderung
- Key Program of National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Nuclear Technology R&D Program
- Shanghai Collaborative Innovation Project
- National Natural Science Foundation of China
- Shanghai Oriental Talents Program Youth Project
Zitieren
APA
Li, Y., Sun, Y., Sun, L., Wang, D., Pan, X., Xu, X., & Song, S. (2026). Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8568-8581. https://doi.org/10.1007/s00259-026-08177-7
Vancouver
Li Y, Sun Y, Sun L, Wang D, Pan X, Xu X, et al. Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8568-8581. doi:10.1007/s00259-026-08177-7
BibTeX
@article{Li2026,
author = {Li, Ye and Sun, Yuyun and Sun, Li and Wang, Dongliang and Pan, Xiaoyu and Xu, Xiaoping and Song, Shaoli},
title = {Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8568--8581},
doi = {10.1007/s00259-026-08177-7}
}
EUVIMED